A short video on what else people may be losing besides fat while on tirzepatide, a point raised often around muscle loss on GLP-1 drugs.
Recap by typeshit. Full story at The Jacquemin Protocol.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
In 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide, 40.7% lost at least 5% more in three months. Data shown at EASD, not yet peer reviewed.
The advisory committee voted to return six peptides barred in 2023, over FDA staff objections. The author argues the GLP-1 shortage proved compounders can deliver.
Loading…